Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Laduviglusib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 10/20 | 0.76 |
| ▸ | CDK1 | P06493 | 3/20 | 0.76 |
| ▸ | GSK3A | P49840 | 3/20 | 0.76 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.76 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.76 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.76 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.76 |
| ▸ | CDK2 | P24941 | 1/20 | 0.76 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.76 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.76 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.76 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.76 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.76 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Laduviglusib SCHEMBL240280 | 0.99 | GSK3B (0.77) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| Laduviglusib SCHEMBL29838591 | 0.99 | GSK3B (0.77) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| Laduviglusib SCHEMBL29381114 | 0.99 | GSK3B (0.77) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL12552315 | 0.92 | GSK3B (0.67) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL5094723 | 0.92 | GSK3B (0.66) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL4398952 | 0.91 | GSK3B (0.65) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL4404427 | 0.91 | GSK3B (0.64) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL20095066 | 0.89 | GSK3B (0.72) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL26489229 | 0.89 | GSK3B (0.62) | GSK3BCDK1GSK3ACCNB2CCNB1 | |
| SCHEMBL7148131 | 0.89 | GSK3B (0.71) | GSK3BCDK1GSK3ACCNB2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943090-A1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | Massachusetts Eye & Ear Infirmary (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3407901-B1 | EXPANSION AND DIFFERENTIATION OF INNER EAR SUPPORTING CELLS AND METHODS OF USE THEREOF | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-106367390-B | Neuron cell culture solution and culture method | 上海爱萨尔生物科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-106479980-B | Neural stem cell culture solution and culture method | 上海爱萨尔生物科技有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-105441381-B | Method of the external evoked human adipose mesenchymal stem cells to functional hepatocyte differentiation | 四川大学 | 2019-03-05 | — | — | CN | disclosed |
| US-20170165230-A1 | USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY | RUDD CHRISTOPHER (CA) | 2017-06-15 | — | — | US | disclosed |
| CN-105441381-A | Method for inducing differentiation of hADSCs (human adipose-derived mesenchymal stem cells) to functional iHeps in vitro | UNIV SICHUAN | 2016-03-30 | — | — | CN | disclosed |
| WO-2015155738-A2 | USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY | RUDD CHRISTOPHER (US) | 2015-10-15 | — | — | WO | disclosed |